Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
A dose-related increase in immune response, as measured by anti-chikungunya virus serum neutralizing antibodies (SNA), was previously observed. Two years post-vaccination, SNA mean titers were 19...
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT
GAITHERSBURG, Md. , May 06, 2021 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2021 Annual Meeting of Stockholders will be held in a virtual-only format via...
Emergent BioSolutions Reports Financial Results for First Quarter 2021
Revises 2021 Financial Forecast GAITHERSBURG, Md. , April 29, 2021 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter ended March...
Statement on Issuance of Form FDA 483 at Emergent Bayview Facility
GAITHERSBURG, Md. , April 21, 2021 (GLOBE NEWSWIRE) — The U.S. Food and Drug Administration (FDA) has completed its inspection of Emergent BioSolutions’ (NYSE:EBS) Baltimore -Bayview facility...
Emergent BioSolutions to Release First Quarter 2021 Financial Results and Conduct a Conference Call on April 29, 2021
GAITHERSBURG, Md. , April 15, 2021 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 29, 2021 at 5:00 pm eastern time to discuss the...
Emergent BioSolutions On Track with Respect to COVID-19 Contractual Commitments; Receives Modified Task Order from the U.S. Department of Health & Human Services to Support the Opportunity for Further Expansion of Manufacturing Capacity for Johnson & Johnson’s COVID-19 Vaccine
HHS has increased Emergent’s task order by $23 million to purchase additional biologics manufacturing equipment Reaffirms 2021 financial guidance GAITHERSBURG, Md. , April 04, 2021 (GLOBE NEWSWIRE)...
Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19
GAITHERSBURG, Md. , April 02, 2021 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today provided an update on the evaluation of its investigational SARS-CoV-2 Immune Globulin...
Company Statement: Emergent BioSolutions Statement on Status of Current Manufacturing of COVID-19 Vaccine at Company’s Baltimore Bayview Facility
At Emergent, safety and quality are our top priorities. Our Bayview facility has been designed and validated to meet all current Good Manufacturing Practices. In addition, there are rigorous quality...
Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
Reports record fourth quarter and year to date 2020 performance, in line with prior guidance Reaffirms full year 2021 forecast GAITHERSBURG, Md. , Feb. 18, 2021 (GLOBE NEWSWIRE) — Emergent...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021
GAITHERSBURG, Md. , Feb. 04, 2021 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 18, 2021 at 5:00 pm eastern time to discuss the...
Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™
GAITHERSBURG, MD. and BURLINGAME, CA. – Jan. 25, 2021 — Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc. (NASDAQ:HGEN) (Humanigen) today announced that they have entered into...
Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results
Expects continued strong financial and operating momentum in 2021, forecasting total revenues of $2 billion at the midpoint and Adjusted EBITDA of $780 million at the midpoint, both increases...